Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Alza files patent infringement suit against Impax in connection with Concerta

Impax Laboratories, Inc. today confirms that Alza Corporation has filed suit for patent infringement against Impax in the United States District Court for the District of Delaware in connection with Concerta® (methylphenidate hydrochloride) extended-release 54 mg tablets.

30 Nov 2010

New pediatric therapy centres in Westmount and Pointe Claire

Parents know the joy when their child begins to lift their head, starts to turn over, say their first word and begins to read. For the family of a child who suffers from a developmental delay or disorder what happens after this discovery is not always simple. In many cases seeing a professional can be challenging. Collage Pediatric Therapy launched private pediatric therapy centres in Westmount and Pointe Claire to provide families with this additional resource and means of accessing the expertise and answers they need to be able to intervene at the earliest stage in their child's development.

25 Nov 2010

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

15 Nov 2010

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

12 Nov 2010

Children with hypertension more likely to have learning disabilities, ADHD

Children who have hypertension are much more likely to have learning disabilities than children with normal blood pressure, according to a new University of Rochester Medical Center (URMC) study published this week in the journal, Pediatrics. In fact, when variables such as socio-economic levels are evened out, children with hypertension were four times more likely to have cognitive problems.

10 Nov 2010

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD) in adults. ND0801, based on a new, proprietary combination with nicotinic actions, is being developed as a dermal patch and will be evaluated for the treatment of cognitive impairment in several disorders including Alzheimer's disease, schizophrenia and advanced Parkinson's disease, among others.

9 Nov 2010

Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

Pisgah Labs, Inc., an innovative drug development and active ingredient manufacturer located in Western North Carolina, has received a substantial federal grant.

4 Nov 2010

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA (methylphenidate HCl extended-release tablets).

3 Nov 2010

Watson enters exclusive agreement with OMJPI to market authorized generic Concerta

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

2 Nov 2010

CONCERTA improves handwriting performance in children with ADHD: Study

Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.

30 Oct 2010

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

Mary Ann Liebert launches Brain Connectivity journal

Mary Ann Liebert, Inc. announces the release of a new peer-reviewed journal in an expanding area of systems neuroscience, Brain Connectivity. This timely new journal is positioned to become the premier source of cutting-edge basic and clinical neuroscience research aimed at better understanding of structural and functional connections in the brain and how these connections are altered by neurological disorders.

29 Oct 2010

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Shire plc the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone.

29 Oct 2010

Developmental-Behavioral Pediatrics Research Network to focus on neurodevelopmental disabilities

Recognizing both medical progress and unmet needs in the field of developmental disabilities, The Children's Hospital of Philadelphia will house the Network Coordinating Center for a newly established collaborative organization, the Developmental-Behavioral Pediatrics Research Network.

14 Oct 2010

Researchers use brain imaging to differentiate pediatric bipolar disorder, ADHD

Researchers at the University of Illinois at Chicago are the first to use brain imaging to examine the effects of emotion on working memory function in children with pediatric bipolar disorder or attention deficit hyperactivity disorder.

13 Oct 2010

Cincinnati Children's, Nationwide Children's Hospital collaborate to improve ADHD care

Doctors at Cincinnati Children's Hospital Medical Center and Nationwide Children's Hospital are collaborating to help pediatricians deliver better care to children with ADHD.

12 Oct 2010

Study: Neurons interact to drive decision-making

We know that casting a ballot in the voting booth involves politics, values and personalities. But before you ever push the button for your candidate, your brain has already carried out an election of its own to make that action possible. New research from Vanderbilt University reveals that our brain accumulates evidence when faced with a choice and triggers an action once that evidence reaches a tipping point.

12 Oct 2010

NCQA recertifies Lilly's online Health Education Answers program

Lilly's Health Education Answers program, an interactive online health and wellness tool, has received Health Information Product Recertification from the National Committee for Quality Assurance (NCQA).

11 Oct 2010

Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD

Targacept, Inc. today announced top-line results from a Phase 2 clinical trial of AZD1446 conducted by AstraZeneca in adults with attention deficit/hyperactivity disorder (ADHD).

8 Oct 2010

Study: 18% of children with ADHD suffered from depression as adolescents

Children diagnosed with attention deficit/hyperactivity disorder (ADHD) at ages 4 to 6 are more likely to suffer from depression as adolescents than those who did not have ADHD at that age, according to a long-term study published in the October issue of the Archives of General Psychiatry. Although it was an uncommon occurrence, the children with ADHD also were somewhat more likely to think about or attempt suicide as adolescents.

5 Oct 2010

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Alza files patent infringement suit against Impax in connection with Concerta

New pediatric therapy centres in Westmount and Pointe Claire

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Children with hypertension more likely to have learning disabilities, ADHD

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Watson enters exclusive agreement with OMJPI to market authorized generic Concerta

CONCERTA improves handwriting performance in children with ADHD: Study

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Mary Ann Liebert launches Brain Connectivity journal

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Developmental-Behavioral Pediatrics Research Network to focus on neurodevelopmental disabilities

Researchers use brain imaging to differentiate pediatric bipolar disorder, ADHD

Cincinnati Children's, Nationwide Children's Hospital collaborate to improve ADHD care

Study: Neurons interact to drive decision-making

NCQA recertifies Lilly's online Health Education Answers program

Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD

Study: 18% of children with ADHD suffered from depression as adolescents

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in